Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer

被引：0

作者：

Govindan, R. ^{[1
]}

Fakih, M. ^{[2
]}

Price, T. ^{[3
]}

Falchook, G. ^{[4
]}

Desai, J. ^{[5
]}

Kuo, J. ^{[6
]}

Strickler, J. ^{[7
]}

Krauss, J. ^{[8
]}

Li, B. ^{[9
]}

Denlinger, C. ^{[10
]}

Durm, G. ^{[11
]}

Ngang, J. ^{[12
]}

Henary, H. ^{[12
]}

Ngarmchamnanrith, G. ^{[12
]}

Rasmussen, E. ^{[12
]}

Morrow, P. K. ^{[12
]}

Hong, D. ^{[13
]}

机构：

[1] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Queen Elizabeth Hosp, Woodville South, Australia

[4] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Scientia Clin Res, Randwick, NSW, Australia

[7] Duke Univ, Med Ctr, Durham, NC 27706 USA

[8] Univ Michigan, Ann Arbor, MI 48109 USA

[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[12] Amgen Inc, Thousand Oaks, CA 91320 USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期

关键词：

AMG; 510; lung cancer; KRAS G12C; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA01.06

引用

页码：S1125 / S1126

页数：2

共 50 条

[1] Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer
Govindan, R.
Fakih, M. G.
Price, T. J.
Falchook, G. S.
Desai, J.
Kuo, J. C.
Strickler, J. H.
Krauss, J. C.
Li, B. T.
Denlinger, C. S.
Durm, G.
Ngang, J.
Henary, H.
Ngarmchamnanrith, G.
Rasmussen, E.
Morrow, P. K.
Hong, D. S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1191 - S1192
[2] Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang, Shannon S.
Nagasaka, Misako
LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 115 - 122
[3] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
Ganguly, Arghya
Yoo, Euna
TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
[4] Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
Govindan, R.
Fakih, M.
Price, T.
Falchook, G.
Desai, J.
Kuo, J.
Strickler, J.
Krauss, J.
Li, B.
Denlinger, C.
Durm, G.
Ngang, J.
Henary, H.
Ngarmchamnanrith, G.
Rasmussen, E.
Morrow, P.
Hong, D.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S208
[5] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Blaquier, Juan Bautista
Cardona, Andres Felipe
Recondo, Gonzalo
FRONTIERS IN ONCOLOGY, 2021, 11
[6] CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
Fakih, Marwan
Desai, Jayesh
Kuboki, Yasutoshi
Strickler, John H.
Price, Timothy Jay
Durm, Greg Andrew
Falchook, Gerald Steven
Denlinger, Crystal S.
Krauss, John C.
Shapiro, Geoffrey
Kim, Tae Won
Park, Keunchil
Coveler, Andrew L.
Munster, Pamela N.
Li, Bob T.
Kim, June
Henary, Haby Adel
Ngarmchamnanrith, Gataree
Hong, David S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Fakih, Marwan
O'Neil, Bert
Price, Timothy Jay
Falchook, Gerald Steven
Desai, Jayesh
Kuo, James
Govindan, Ramaswamy
Rasmussen, Erik
Morrow, Phuong Khanh H.
Ngang, Jude
Henary, Haby A.
Hong, David S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Hong, David S.
Kuo, James
Sacher, Adrian G.
Barlesi, Fabrice
Besse, Benjamin
Kuboki, Yasutoshi
Dy, Grace K.
Dembla, Vikas
Krauss, John C.
Burns, Timothy F.
Kim, June
Henary, Haby
Ngarmchamnanrith, Gataree
Li, Bob T.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Advances in the treatment of KRASG12C mutant non-small cell lung cancer
Shaverdashvili, Khvaramze
Burns, Timothy F.
CANCER, 2025, 131
[10] An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations
Strohbehn, Garth W.
Sankar, Kamya
Qin, Angel
Kalemkerian, Gregory P.
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (14) : 1569 - 1575

← 1 2 3 4 5 →